Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
- 1Research Laboratory of Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest, Hungary
2Laboratory of Functional Genomics, Institute of Pathology, Charité, Berlin, Germany
32nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary
4Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
5Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- (Correspondence should be addressed to B Győrffy who is now at First Department of Pediatrics, Semmelweis University, Bókay János u. 53-54, H-1083 Budapest, Hungary; Email: gyorffy{at}kmplot.com)
-
Figure 1
Survival plots depicting the good prognostic effect on progression-free survival of the lower expression of CA125 (A, 201383_s_at), CDKN1B (B, 209112_at), and P15 (C, 212857_x_at). Classification using the mean expression of two genes (CA125+CDKN1B) with a cutoff at the lower quartile results in increased discriminative power (D).
- © 2012 Society for Endocrinology
